Abstract The coronavirus disease 2019 (Covid-19) outbreak is evolving rapidly worldwide. The Lung is the target organ of the primary infection and patient whit lung cancer seems to have a poor prognosis. This is the first reported investigation on a possible role of IL 17 target therapy in Lung Cancer patients with concomitant Sars-CoV2 infection.